Cargando…

Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge

Designing immunogens and improving delivery methods eliciting protective immunity is a paramount goal of HIV vaccine development. A comparative vaccine challenge study was performed in rhesus macaques using clade C HIV Envelope (Env) and SIV Gag antigens. One group was vaccinated using co-immunizati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malherbe, Delphine C., Vang, Lo, Mendy, Jason, Barnette, Philip T., Spencer, David A., Reed, Jason, Kareko, Bettie W., Sather, D. Noah, Pandey, Shilpi, Wibmer, Constantinos K., Robins, Harlan, Fuller, Deborah H., Park, Byung, Lakhashe, Samir K., Wilson, James M., Axthelm, Michael K., Ruprecht, Ruth M., Moore, Penny L., Sacha, Jonah B., Hessell, Ann J., Alexander, Jeff, Haigwood, Nancy L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917243/ https://www.ncbi.nlm.nih.gov/pubmed/33658998 http://dx.doi.org/10.3389/fimmu.2020.626464

Ejemplares similares

Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development
por: Malherbe, Delphine C., et al.
Publicado: (2020)

R5 Clade C SHIV Strains with Tier 1 or 2 Neutralization Sensitivity: Tools to Dissect Env Evolution and to Develop AIDS Vaccines in Primate Models
por: Siddappa, Nagadenahalli B., et al.
Publicado: (2010)

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in newborn macaques
por: Hessell, Ann J., et al.
Publicado: (2016)

Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity
por: Shapiro, Mariya B., et al.
Publicado: (2020)

Vaccination against Heterologous R5 Clade C SHIV: Prevention of Infection and Correlates of Protection
por: Lakhashe, Samir K., et al.
Publicado: (2011)

Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines
por: Weiss, Svenja, et al.
Publicado: (2022)

Passive immunization with polyclonal anti-SHIV IgG: partial protection or increased acquisition of heterologous tier 2 SHIV – depending on IgG dose
por: Sholukh, AM, et al.
Publicado: (2012)

Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose
por: Sholukh, Anton M, et al.
Publicado: (2014)

Native envelope-based immunogens derived from critical timepoints in the development of breadth elicit rapid neutralizing antibodies in rabbits
por: Malherbe, DC, et al.
Publicado: (2012)

An Anti-HIV-1 V3 Loop Antibody Fully Protects Cross-Clade and Elicits T-Cell Immunity in Macaques Mucosally Challenged with an R5 Clade C SHIV
por: Watkins, Jennifer D., et al.
Publicado: (2011)

Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques
por: Wen, Jing, et al.
Publicado: (2021)

Complement contributes to antibody-mediated protection against repeated SHIV challenge
por: Goldberg, Benjamin S., et al.
Publicado: (2023)

Schistosoma mansoni Enhances Host Susceptibility to Mucosal but Not Intravenous Challenge by R5 Clade C SHIV
por: Siddappa, Nagadenahalli B., et al.
Publicado: (2011)

Variations in the Biological Functions of HIV-1 Clade C Envelope in a SHIV-Infected Rhesus Macaque during Disease Progression
por: Tso, For Yue, et al.
Publicado: (2013)

Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques
por: Jaworski, Juan Pablo, et al.
Publicado: (2017)

Dynamics of Envelope Evolution in Clade C SHIV-Infected Pig-Tailed Macaques during Disease Progression Analyzed by Ultra-Deep Pyrosequencing
por: Tso, For Yue, et al.
Publicado: (2012)

Acute Schistosoma mansoni Infection Increases Susceptibility to Systemic SHIV Clade C Infection in Rhesus Macaques after Mucosal Virus Exposure
por: Chenine, Agnès-Laurence, et al.
Publicado: (2008)

Antimicrobial prophylaxis does not improve post-surgical outcomes in SIV/SHIV-uninfected or SIV/SHIV-infected macaques (Macaca mulatta and Macaca fascicularis) based on a retrospective analysis
por: Moats, Cassandra, et al.
Publicado: (2022)

SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys
por: Humbert, Michael, et al.
Publicado: (2008)

Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission
por: Chang, Xiao L., et al.
Publicado: (2021)

Cooperation Between Systemic IgG1 and Mucosal Dimeric IgA2 Monoclonal Anti-HIV Env Antibodies: Passive Immunization Protects Indian Rhesus Macaques Against Mucosal SHIV Challenges
por: Gong, Siqi, et al.
Publicado: (2021)

Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers
por: Pauthner, Matthias G., et al.
Publicado: (2019)

Cooperation Between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques Against Low-Dose Intravaginal SHIV Challenges
por: Lakhashe, Samir K., et al.
Publicado: (2022)

The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques
por: Webb, Gabriela M., et al.
Publicado: (2020)

Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques
por: Ng, Cherie T., et al.
Publicado: (2010)

Efficacy of silk fibroin biomaterial vehicle for in vivo mucosal delivery of Griffithsin and protection against HIV and SHIV infection ex vivo
por: Crakes, Katti R, et al.
Publicado: (2020)

Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic
por: Spencer, David A., et al.
Publicado: (2021)

Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1 antibody repertoire in the absence of viremia
por: Bachler, Barbara C, et al.
Publicado: (2013)

Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers
por: Hessell, Ann J., et al.
Publicado: (2009)

Atlas operation in the GridKa Tier1/Tier2 Cloud
por: Nderitu, S, et al.
Publicado: (2010)

Atlas operation in the GridKa Tier1/Tier2 Cloud
por: Nderitu, S, et al.
Publicado: (2011)

Role of Tier-0, Tier-1 and Tier-2 Regional Centers in CMS DC04
por: Barrass, T, et al.
Publicado: (2004)

Shiv Nadar School students visit CERN
por: Poulaillon, Jimmy, et al.
Publicado: (2023)

Oral Vaccination Approaches for Anti-SHIV Immunity
por: Velarde de la Cruz, Erandi, et al.
Publicado: (2021)

Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis
por: Spencer, David A., et al.
Publicado: (2022)

Identification of a clade A HIV envelope immunogen from Protocol G that elicits neutralizing antibodies to tier 2 viruses
por: Hoffenberg, S, et al.
Publicado: (2012)

Mucosal AIDS virus transmission is enhanced by antiviral IgG isolated early in infection
por: Marasini, Bishal, et al.
Publicado: (2021)

Simian-Human Immunodeficiency Virus SHIV.C.CH505 Persistence in ART-Suppressed Infant Macaques Is Characterized by Elevated SHIV RNA in the Gut and a High Abundance of Intact SHIV DNA in Naive CD4(+) T Cells
por: Obregon-Perko, Veronica, et al.
Publicado: (2020)

Antibody mediated protection of immunized macaques against pathogenic SHIV challenge
por: Srivastava, Indresh K, et al.
Publicado: (2006)

Potency and breadth of human primary ZIKV immune sera shows that Zika viruses cluster antigenically as a single serotype
por: Nix, Chad D., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_79eqvh7g12u6h3c5omo6c719qd